CONTEXT: Hypotension is one of the dose limiting side effects of benzodiazepines (BZDs), in particular of diazepam (DZP) which is still widely used in the clinic. Currently, only one FDA approved antidote exists for BZD overdose and novel approaches are needed to improve management of DZP overdose, dependency and withdrawal. OBJECTIVE: Here, we hypothesized that increasing bioactive lipid mediators termed epoxy fatty acids (EpFAs) will prevent hypotension, as was shown previously in a murine model of LPS-induced hypotension. Therefore, we first characterized the time and dose dependent profile of DZP induced hypotension in mice, and then investigated the reversal of the hypotensive effect by inhibiting the soluble epoxide hydrolase (sEH), an enzyme that regulates the levels of EpFAs. MATERIALS AND METHODS: Following baseline systolic BP recording using tail cuffs, mice were administered a sEH inhibitor (TPPU) before DZP and BP was monitored. Blood and brain levels of DZP and TPPU were quantified to examine distribution and metabolism. Plasma EpFAs levels were quantified to determine TPPU target engagement. RESULTS: In this murine model, DZP induced dose dependent hypotension which was more severe than midazolam. The temporal profile was consistent with the reported pharmacokinetics/pharmacodynamics of DZP. Treatment with TPPU reversed the hypotension resulting from high doses of DZP and decreased the sEH metabolites of EpFAs in the plasma demonstrating target engagement. DISCUSSION AND CONCLUSION: Overall, these findings demonstrate the similarity of a murine model of DZP induced hypotension to clinical observations in humans. Furthermore, we demonstrate that stabilization of EpFAs by inhibiting sEH is a novel approach to overcome DZP-induced hypotension and this beneficial effect can be enhanced by an omega three diet probably acting through epoxide metabolites of the fatty acids.
CONTEXT: Hypotension is one of the dose limiting side effects of benzodiazepines (BZDs), in particular of diazepam (DZP) which is still widely used in the clinic. Currently, only one FDA approved antidote exists for BZD overdose and novel approaches are needed to improve management of DZPoverdose, dependency and withdrawal. OBJECTIVE: Here, we hypothesized that increasing bioactive lipid mediators termed epoxy fatty acids (EpFAs) will prevent hypotension, as was shown previously in a murine model of LPS-induced hypotension. Therefore, we first characterized the time and dose dependent profile of DZP induced hypotension in mice, and then investigated the reversal of the hypotensive effect by inhibiting the soluble epoxide hydrolase (sEH), an enzyme that regulates the levels of EpFAs. MATERIALS AND METHODS: Following baseline systolic BP recording using tail cuffs, mice were administered a sEH inhibitor (TPPU) before DZP and BP was monitored. Blood and brain levels of DZP and TPPU were quantified to examine distribution and metabolism. Plasma EpFAs levels were quantified to determine TPPU target engagement. RESULTS: In this murine model, DZP induced dose dependent hypotension which was more severe than midazolam. The temporal profile was consistent with the reported pharmacokinetics/pharmacodynamics of DZP. Treatment with TPPU reversed the hypotension resulting from high doses of DZP and decreased the sEH metabolites of EpFAs in the plasma demonstrating target engagement. DISCUSSION AND CONCLUSION: Overall, these findings demonstrate the similarity of a murine model of DZP induced hypotension to clinical observations in humans. Furthermore, we demonstrate that stabilization of EpFAs by inhibiting sEH is a novel approach to overcome DZP-induced hypotension and this beneficial effect can be enhanced by an omega three diet probably acting through epoxide metabolites of the fatty acids.
Authors: John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock Journal: Hypertension Date: 2005-09-12 Impact factor: 10.190
Authors: Hécio Henrique Araújo de Morais; Jimmy Charles Melo Barbalho; Ricardo José de Holanda Vasconcellos; Fabricio Souza Landim; Fábio Andrey da Costa Araújo; Tasiana Guedes de Souza Dias Journal: Oral Maxillofac Surg Date: 2015-02-25
Authors: Arzu Ulu; Todd R Harris; Christophe Morisseau; Christina Miyabe; Hiromi Inoue; Gertrud Schuster; Hua Dong; Ana-Maria Iosif; Jun-Yan Liu; Robert H Weiss; Nipavan Chiamvimonvat; John D Imig; Bruce D Hammock Journal: J Cardiovasc Pharmacol Date: 2013-09 Impact factor: 3.105
Authors: Guodong Zhang; Dipak Panigrahy; Lisa M Mahakian; Jun Yang; Jun-Yan Liu; Kin Sing Stephen Lee; Hiromi I Wettersten; Arzu Ulu; Xiaowen Hu; Sarah Tam; Sung Hee Hwang; Elizabeth S Ingham; Mark W Kieran; Robert H Weiss; Katherine W Ferrara; Bruce D Hammock Journal: Proc Natl Acad Sci U S A Date: 2013-04-03 Impact factor: 11.205
Authors: Arzu Ulu; Kin Sing Stephen Lee; Christina Miyabe; Jun Yang; Bruce G Hammock; Hua Dong; Bruce D Hammock Journal: J Cardiovasc Pharmacol Date: 2014-07 Impact factor: 3.105
Authors: Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan Journal: Prog Neurobiol Date: 2018-11-14 Impact factor: 11.685
Authors: Bora Inceoglu; Ahmed Bettaieb; Fawaz G Haj; Aldrin V Gomes; Bruce D Hammock Journal: Prostaglandins Other Lipid Mediat Date: 2017-08-25 Impact factor: 3.072
Authors: Arzu Ulu; Jalene V Velazquez; Abigail Burr; Stefanie N Sveiven; Jun Yang; Carissa Bravo; Bruce D Hammock; Tara M Nordgren Journal: Front Pharmacol Date: 2022-01-13 Impact factor: 5.810
Authors: Frances M Potjewyd; Joel K Annor-Gyamfi; Jeffrey Aubé; Shaoyou Chu; Ivie L Conlon; Kevin J Frankowski; Shiva K R Guduru; Brian P Hardy; Megan D Hopkins; Chizuru Kinoshita; Dmitri B Kireev; Emily R Mason; Charles T Moerk; Felix Nwogbo; Kenneth H Pearce; Timothy I Richardson; David A Rogers; Disha M Soni; Michael Stashko; Xiaodong Wang; Carrow Wells; Timothy M Willson; Stephen V Frye; Jessica E Young; Alison D Axtman Journal: Alzheimers Dement (N Y) Date: 2022-04-12